Streetbeat News

Revenues

SUPN

Supernus Pharmaceuticals projects its FY24 total revenue to be between $580M and $620M, which is below the estimated $622.52M.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:15 pm

SAFT

Safety Insurance Group (SAFT) reported Q4 2023 adjusted EPS of $0.30, missing the $0.77 estimate, a 69.39% decrease from last year's $0.98. Sales rose 17.02% YoY to $226.03M from $193.15M.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:14 pm

MYGN

Myriad Genetics projects its adjusted EPS for 2024 to be between $0.00 and $0.05, surpassing the estimated $(0.01), and forecasts revenue to be between $820M and $840M, slightly above the estimated $819.25M.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:08 pm

ARKO

ARKO reported Q4 sales of $2.23 billion, missing the analyst consensus estimate of $2.43 billion by 8.10%. This represents a 2.43% increase over the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:07 pm

ALEC

Alector anticipates collaboration revenue of $60M-$70M for 2024, with total R&D expenses projected to be between $210M-$230M.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:04 pm

BCSF

Bain Capital Specialty (BCSF) reported Q4 2023 earnings of $0.54 per share, meeting analyst estimates. Quarterly sales reached $74.95M, surpassing the $64.99M estimate by 15.32%, and marking a 28.43% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 10:03 pm

LMND

Lemonade anticipates accelerating top line growth and an improving bottom line in 2024, with plans to become cash flow positive in 2025 and achieve adjusted EBITDA positivity in 2026.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 9:56 pm

ACAD

Acadia Pharmaceuticals projects 2024 net product sales for DAYBUE to be between $370M-$420M and for NUPLAZID to be between $560M-$590M.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 9:55 pm

TUYA

Tuya Inc. (TUYA) reported Q4 2023 earnings of $0.02 per share, meeting analyst expectations. Quarterly sales reached $64.41M, surpassing the $61.72M forecast by 4.36% and marking a 42.23% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 9:54 pm

BMBL

Bumble anticipates an 8%-11% revenue growth for the fiscal year 2024, indicating a positive outlook for the company's financial performance.

Portfolio Pulse from Benzinga Newsdesk

February 27, 2024 | 9:53 pm